about
New concept of myocardial longitudinal strain reserve assessed by a dipyridamole infusion using 2D-strain echocardiography: the impact of diabetes and age, and the prognostic value.Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners.Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology.The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer.Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence.Prediction of all-cause mortality from gated-SPECT global myocardial wall thickening: comparison with ejection fraction and global longitudinal 2D-strain.Is TOMPOOL (gated blood-pool SPECT processing software) accurate to diagnose right and left ventricular dysfunction in a clinical setting?The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer.Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).Diagnostic and prognostic value of 18F-FDG PET, CT, and MRI in perineural spread of head and neck malignancies.Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor.[Hodgkin lymphoma: Current and future therapeutic strategies].Towards multi-phase postmortem CT angiography in children: a study on a porcine model.[Computational medical imaging (radiomics) and potential for immuno-oncology].Gated blood pool SPECT: The estimation of right ventricular volume and function is algorithm dependent in a clinical setting.Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.Interobserver variability in tumor contouring affects the use of radiomics to predict mutational status.Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.Study of a seventeenth-century French artificial mummy: autopsical, native, and contrast-injected CT investigations.Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer.Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours.Spleno-hepatic index to predict portal hypertension by equilibrium radionuclide ventriculographyCT Slice Thickness and Convolution Kernel Affect Performance of a Radiomic Model for Predicting EGFR Status in Non-Small Cell Lung Cancer: A Preliminary StudyA radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort studyIncreased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapyEvaluation of 2 diuretic 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography imaging protocols for intrapelvic cancerAbscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibodyProlonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphomaRadiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR PathwayEfficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuationDiagnosis of Hyper-progressive Disease in Patients Treated with Checkpoint Inhibitors using 18F-FDG PET/CTFLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With PembrolizumabIdentification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using RadiomicsPrognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4Radiomics in Nuclear Medicine Applied to Radiation Therapy: Methods, Pitfalls, and ChallengesEarly 18F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab
P50
Q36937350-DD9FC21F-C7E5-4C96-8A49-6648BEB14827Q38264850-E351C7A3-58D4-4A5B-8F51-8B72B10C3B14Q38748715-A5677C98-3C26-4334-BBEF-C840EC2E19A1Q38975066-76EE9AF7-B80C-487F-BC4C-7BB76B2CBC08Q40504163-F60F99F3-31D7-4ED2-BB15-7FE8B90FB652Q41366729-E44D2D22-013B-41DE-9C49-F87C2A867532Q43498556-603899F7-7BB5-41BE-92B5-53D612FE884AQ46001484-19CB2A0F-3188-4EF2-90D5-CCC0176E1308Q46876969-101F1B33-BD33-4F47-9A75-31FDC739F069Q47416333-16F48646-6128-4662-9DA8-AC56FC274BFFQ47668675-D744D441-FBD4-4EBB-84C4-887F6CCC7211Q47927037-01202D10-709B-4053-981B-44CD814EE038Q48099236-58DC819B-6FA8-4277-8B95-8CC54D342174Q48513573-B77113BB-C1CC-4E6E-B90A-401C81DB827CQ48636721-760C2E2F-468F-4293-BF07-1E9596D17431Q49387724-3F699C1E-73F4-4ED4-96E6-8687BCFCE12BQ49588466-FE59F854-FF07-4CB5-861C-7DE979E2F184Q50491125-A1C18F4A-F843-4189-BB96-9B03FA7A9AECQ50957068-BFE72242-675F-4489-8540-E0A6F8987DB3Q51621001-A26D9D63-7DB4-45D9-BD39-B7C4208FB81AQ52446289-923049AB-C2FE-4A1A-8F0B-263BEBE09865Q52560944-E5790EEA-4262-45F1-93FB-F7B71F3C249AQ52623989-D557085B-0D5D-4886-855B-0B4178E851DFQ52984601-1B2EE2F5-5609-44C0-B3F7-187DD95D1F22Q54982898-B49946E4-7F96-44C7-B544-3EB994B9F84AQ58115763-96CB7C93-E7CC-4F81-8EC5-8013A6CA06B0Q60301839-1AFC0095-2FFE-4A60-9DD9-E78FDC435184Q61948598-32D84F40-FEAC-4FE3-A071-2AD8C28493E3Q64058245-111358B6-9FD0-47A7-A766-A9C13AE99A01Q87706010-48445DB1-B74C-4629-A2F4-91E360AC1223Q88168570-7CEB77D7-B0ED-41B5-A5D6-A507883BF136Q88561877-C890F2AC-E335-4ACE-8B1B-440C00805D15Q89522016-68230910-54AA-4108-9D63-416EB117D677Q89700338-E70061F9-07A4-4CC7-92BE-B94C072EB5B3Q89837432-479F1855-4178-4644-BD0B-46B17D250FE7Q89933384-18FA10D2-9288-4B48-BBD9-F9D26EA9DE5BQ90537937-C7EC3DF3-87F4-46B0-A77E-7FB563DABF32Q90614202-67DCE36B-C64A-4939-88B4-7D6BC70B01FBQ90669299-CAA3FF11-AC53-4A63-8110-334CC2F3C786Q90810963-31FB0376-0C00-4E9A-87FC-173B8BDE1BF9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laurent Dercle
@ast
Laurent Dercle
@en
Laurent Dercle
@es
Laurent Dercle
@nl
Laurent Dercle
@sl
type
label
Laurent Dercle
@ast
Laurent Dercle
@en
Laurent Dercle
@es
Laurent Dercle
@nl
Laurent Dercle
@sl
prefLabel
Laurent Dercle
@ast
Laurent Dercle
@en
Laurent Dercle
@es
Laurent Dercle
@nl
Laurent Dercle
@sl
P106
P31
P496
0000-0002-1322-0710